CompletedNot Applicable

Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer

Argentina, Chile, Colombia601 participantsStarted 2021-03-04

Plain-language summary

This prospective, multicountry, multicentre, non-interventional study plans to include patients who have undergone surgery for early-stage (IA to IIIB on the basis of pathologic criteria) non-squamous NSCLC up to 6 weeks prior to enrolment into the study. The main objective of this study is to determine the prevalence of EGFRm in patients with surgically resected early-stage (IA to IIIB) non-squamous NSCLC as there are limited data on its prevalence in this patient population.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Histology of the tumour is considered not to be of primary lung in origin
✕. Histology is pure squamous cell carcinoma, pure small cell carcinoma, or large cell carcinoma origin lacking any immunohistochemistry evidence of adenocarcinoma differentiation -

What they're measuring

Overall proportion of patients with EGFRm

Timeframe: 3 month

Proportion of EGFRm in Pathologic Stage

Timeframe: 3 Month

Trial details

NCT IDNCT04742192

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2022-11-30

View on ClinicalTrials.gov More Non-small Cell Lung Cancer trials